Ocuphire Pharma/OCUP

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Ocuphire Pharma

Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1α and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Company’s pipeline candidates include APX2009 and APX2014. The Company is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.

Ticker

OCUP

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

George Magrath

Employees

14

Headquarters

Farmington hills, United States

Ocuphire Pharma Metrics

BasicAdvanced
$44M
Market cap
-
P/E ratio
-$0.49
EPS
0.35
Beta
-
Dividend rate
$44M
0.34781
$4.58
$1.50
221K
8.959
-9.73%
-23.24%
-25.89%
-25.89%
2.291
0.915
0.946
-54.30%
-170.01%

What the Analysts think about Ocuphire Pharma

Analyst Ratings

Majority rating from 4 analysts.
Buy

Ocuphire Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-417.64% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.7M
6.25%
Net income
-$7.1M
51.06%
Profit margin
-417.64%
42.18%

Ocuphire Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 116.42%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.24
$0.25
-$0.21
-$0.29
-
Expected
-$0.23
-$0.22
-$0.05
-$0.13
-$0.24
Surprise
6.19%
-212.61%
300.00%
116.42%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Ocuphire Pharma stock?

Ocuphire Pharma (OCUP) has a market cap of $44M as of June 15, 2024.

What is the P/E ratio for Ocuphire Pharma stock?

The price to earnings (P/E) ratio for Ocuphire Pharma (OCUP) stock is 0 as of June 15, 2024.

Does Ocuphire Pharma stock pay dividends?

No, Ocuphire Pharma (OCUP) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next Ocuphire Pharma dividend payment date?

Ocuphire Pharma (OCUP) stock does not pay dividends to its shareholders.

What is the beta indicator for Ocuphire Pharma?

Ocuphire Pharma (OCUP) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Ocuphire Pharma stock price target?

The target price for Ocuphire Pharma (OCUP) stock is $19, which is NaN% below the current price of $. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Ocuphire Pharma stock

Buy or sell Ocuphire Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing